Chapter Title: Disease-Modifying Anti‑Rheumatic Drugs (DMARDs)

Introduction/Overview

Brief Introduction to the Topic

DMARDs constitute a heterogeneous group of pharmacologic agents that have been developed to modify the underlying disease process in rheumatic disorders. The principal objective of these medications is to suppress inflammatory pathways, thereby reducing joint damage and preserving functional capacity. Over the past several decades, advances in immunology and molecular biology have expanded the repertoire of DMARDs from conventional synthetic agents to biologic and targeted synthetic drugs.

Clinical Relevance and Importance

Rheumatoid arthritis (RA) and related inflammatory arthritides impose a significant burden on patients and healthcare systems worldwide. Early and sustained disease control is associated with improved long‑term outcomes, decreased disability, and lower rates of cardiovascular morbidity. Consequently, the judicious selection and monitoring of DMARD therapy remain central to contemporary rheumatologic practice.

Learning Objectives

• Understand the classification and chemical diversity of DMARDs.
• Describe the pharmacodynamic mechanisms underlying each drug class.
• Summarize pharmacokinetic properties relevant to dosing and monitoring.
• Identify approved indications, common adverse effects, and safety considerations.
• Apply knowledge of drug interactions and special patient populations to clinical decision‑making.

Classification

Drug Classes and Categories

DMARDs are traditionally divided into three categories:

1. Conventional Synthetic DMARDs (csDMARDs) – small molecules developed before the advent of biologic therapies.
2. Biologic DMARDs (bDMARDs) – recombinant proteins or monoclonal antibodies targeting specific cytokines or immune cells.
3. Targeted Synthetic DMARDs (tsDMARDs) – small‑molecule inhibitors that modulate intracellular signaling pathways.

Chemical Classification

Within csDMARDs, agents are further categorized by chemical structure:

• Sulfonamides – e.g., sulfasalazine.
• Pyrimidines – e.g., leflunomide.
• Antimetabolites – e.g., methotrexate.
• Antimalarials – e.g., hydroxychloroquine.
• Others – e.g., azathioprine, mycophenolate mofetil.

Mechanism of Action

Conventional Synthetic DMARDs

Methotrexate

Methotrexate exerts its therapeutic effect primarily through inhibition of dihydrofolate reductase, leading to reduced DNA synthesis in rapidly dividing cells, including activated lymphocytes. Additionally, it increases extracellular adenosine levels, which possesses anti‑inflammatory properties by binding to A2A receptors on immune cells and suppressing pro‑inflammatory cytokine release.

Sulfasalazine

Sulfasalazine is metabolized to 5‑aminosalicylic acid and sulfapyridine. The former inhibits cyclooxygenase and lipoxygenase pathways, thereby decreasing prostaglandin and leukotriene production. The sulfapyridine metabolite modulates immune cell function by reducing the activity of T lymphocytes and macrophages.

Leflunomide

Leflunomide is converted to its active metabolite, A77‑1726, which irreversibly inhibits dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine synthesis. Consequently, T and B cell proliferation is curtailed, dampening the autoimmune response.

Hydroxychloroquine

Hydroxychloroquine accumulates within lysosomes of monocytes and macrophages, raising intralysosomal pH and interfering with antigen processing and lysosomal enzyme activity. It also inhibits toll‑like receptor signaling, thereby decreasing interferon production.

Biologic DMARDs

TNF Inhibitors (Etanercept, Infliximab, Adalimumab, Golimumab, Certolizumab Pegol)

These agents bind soluble and membrane‑bound tumor necrosis factor‑α (TNF‑α), preventing its interaction with TNF receptors on target cells. This blockade reduces downstream inflammatory signaling, including NF‑κB activation and cytokine release.

IL‑6 Inhibitors (Tocilizumab, Sarilumab)

IL‑6 receptor antagonists competitively inhibit IL‑6 binding to its receptor complex (IL‑6Rα and gp130), thereby attenuating JAK/STAT signaling cascades. The suppression of acute‑phase reactants and modulation of B‑cell differentiation are notable downstream effects.

CTLA‑4 Ig (Abatacept)

Abatacept binds CD80/CD86 on antigen‑presenting cells, preventing co‑stimulation of CD28 on T cells. The resulting anergy of T cells limits the autoimmune cascade.

B‑cell Depletion (Rituximab)

Rituximab targets CD20 on B cells, inducing apoptosis through complement‑dependent cytotoxicity and antibody‑dependent cell‑mediated cytotoxicity. The reduction in antibody‑producing cells mitigates disease activity.

Janus Kinase (JAK) Inhibitors (Tocilizumab, Upadacitinib, Baricitinib, Filgotinib)

JAK inhibitors competitively bind the ATP site of JAK enzymes, disrupting cytokine receptor signaling. This blockade diminishes transcription of inflammatory genes. Specificity for JAK1, JAK2, or JAK3 varies among agents, influencing efficacy and safety profiles.

Targeted Synthetic DMARDs

Selective JAK Inhibitors

Upadacitinib selectively inhibits JAK1, while baricitinib preferentially blocks JAK1/JAK2. Filgotinib demonstrates a high affinity for JAK1. These agents modulate cytokine signaling pathways implicated in RA pathogenesis.

Janus Kinase Inhibitors

Baricitinib and other JAK inhibitors interfere with signal transduction for cytokines such as IL‑6, IL‑12/23, and interferon‑γ, thereby reducing inflammatory responses.

Pharmacokinetics

Conventional Synthetic DMARDs

Methotrexate

Orally administered methotrexate is absorbed via passive diffusion with peak plasma concentrations reached within 1–2 hours. Bioavailability decreases with higher doses due to saturable transport mechanisms. Distribution is extensive, with a volume of distribution approximating total body water. Metabolism occurs primarily in the liver via polyglutamation and deconjugation, producing inactive metabolites. Renal excretion accounts for the majority of elimination, with a half‑life ranging from 3 to 10 hours depending on renal function. Dose adjustments are necessary in patients with impaired renal clearance.

Sulfasalazine

Absorption is relatively slow, with peak levels occurring 4–6 hours post‑dose. Distribution is moderate, with a volume of distribution of about 0.6–1.0 L/kg. Metabolism in the colon yields 5‑ASA and sulfapyridine. Renal excretion predominates for sulfapyridine metabolites, whereas 5‑ASA is excreted via the biliary route. The half‑life of sulfasalazine is approximately 20–30 hours, supporting once‑daily dosing.

Leflunomide

Leflunomide is rapidly absorbed, achieving peak concentrations within 1–2 hours. Its active metabolite A77‑1726 persists due to enterohepatic recirculation, resulting in a very long half‑life of 15–20 days. Distribution is extensive, with a volume of distribution of 200–400 L. Metabolism occurs via hepatic cytochrome P450 enzymes, and excretion is predominantly renal, necessitating dose adjustments in renal impairment.

Hydroxychloroquine

Hydroxychloroquine is well absorbed orally with peak concentrations by 2–4 hours. Distribution is extensive, with a volume of distribution of 350–400 L. Metabolism occurs in the liver to inactive metabolites, and excretion is primarily renal. The half‑life is exceptionally long (> 30 days), which explains the cumulative toxicity risk with prolonged use.

Biologic DMARDs

Biologic agents are typically administered parenterally (subcutaneous or intravenous). Their absorption is immediate for IV formulations, while subcutaneous administration yields peak concentrations within 1–2 days. Distribution is largely confined to the vascular compartment, with volumes of distribution ranging from 4 to 9 L. Metabolism involves proteolytic degradation by the reticuloendothelial system, and elimination is mediated by renal and hepatic pathways, although the latter is less significant. Half‑lives vary widely: etanercept (~4–5 days), adalimumab (~10–14 days), infliximab (~8–12 days), tocilizumab (~8–11 days). These pharmacokinetic profiles inform dosing intervals ranging from weekly to monthly.

Targeted Synthetic DMARDs

JAK Inhibitors

Orally administered JAK inhibitors exhibit high bioavailability (>70%). Peak plasma concentrations are achieved within 1–2 hours. Distribution is extensive, and metabolism occurs via hepatic cytochrome P450 enzymes (primarily CYP3A4). Excretion is mainly renal. Half‑lives range from 2 to 6 hours, supporting once‑daily dosing schedules. Drug–drug interactions are significant due to CYP3A4 involvement.

Therapeutic Uses/Clinical Applications

Approved Indications

DMARDs are indicated primarily for inflammatory arthritides and connective tissue diseases:

• Rheumatoid arthritis (primary indication for all classes).
• Psoriatic arthritis (csDMARDs and biologics).
• Ankylosing spondylitis (TNF inhibitors).
• Systemic lupus erythematosus (hydroxychloroquine, methotrexate).
• Rheumatic vasculitis (rituximab, cyclophosphamide).
• JIA (juvenile idiopathic arthritis) – methotrexate, biologics.

Off‑Label Uses

Common off‑label applications include:

• Inflammatory bowel disease (TNF inhibitors).
• Gout (IL‑1 inhibitors, though not DMARDs per se).
• Dermatologic conditions such as dermatomyositis (rituximab).
• Autoimmune hepatitis (azathioprine).

Adverse Effects

Conventional Synthetic DMARDs

Methotrexate

Hepatotoxicity manifests as elevated transaminases and, in severe cases, fibrosis. Myelosuppression can lead to anemia, leukopenia, and thrombocytopenia. Pulmonary toxicity is rare but may present as interstitial pneumonitis. Oral ulcerations and gastrointestinal irritation are frequent. Regular monitoring of liver function tests, complete blood counts, and renal function is recommended.

Sulfasalazine

Common adverse events include nausea, vomiting, abdominal discomfort, and headache. Rarely, hypersensitivity reactions such as rash, eosinophilia, and interstitial pneumonitis may occur. Hematologic abnormalities (anemia, leukopenia) are infrequent.

Leflunomide

Hepatic enzyme elevation, rash, and diarrhea are typical. Severe hepatotoxicity can progress to fulminant hepatic failure. The drug’s long half‑life necessitates an elimination protocol using cholestyramine for patients experiencing toxicity.

Hydroxychloroquine

Retinal toxicity is a serious concern, especially with cumulative doses exceeding 5.0 g/year. Other ocular effects include visual field defects. Gastrointestinal upset, skin rash, and myopathy are less common. Baseline ophthalmologic evaluation and periodic follow‑up are essential.

Biologic DMARDs

TNF Inhibitors

Infections, particularly reactivation of latent tuberculosis, pose a significant risk. Infusion reactions and hypersensitivity are possible. Lymphopenia and increased risk of lymphoma have been reported, though causality remains unclear. Monitoring for infections and screening for TB prior to initiation is advised.

IL‑6 Inhibitors

Elevated liver enzymes, neutropenia, and increased cholesterol levels are frequent. Infections and opportunistic pathogens are also noted. Routine laboratory surveillance is advised.

CTLA‑4 Ig

Infusion reactions, hypogammaglobulinemia, and increased risk of infections may occur. Rarely, autoimmune phenomena such as lupus-like syndrome have been observed.

B‑cell Depletion

Infusion reactions, neutropenia, and increased susceptibility to infections, particularly viral reactivations (e.g., hepatitis B), are documented. Long‑term immunosuppression may predispose to malignancies.

Targeted Synthetic DMARDs

JAK Inhibitors

Venous thromboembolism and cardiovascular events have emerged as concerns. Anemia, neutropenia, and increased liver enzymes are also common. The risk is dose‑dependent, necessitating careful cardiovascular assessment before therapy.

Drug Interactions

Major Drug‑Drug Interactions

Conventional synthetic DMARDs often interact with NSAIDs, steroids, and other immunosuppressants, potentially amplifying hepatotoxicity or myelosuppression. Methotrexate is contraindicated with drugs that inhibit renal excretion (e.g., NSAIDs) or potentiate toxicity (e.g., azathioprine). Sulfasalazine may reduce absorption of antacids containing calcium or magnesium.

Biologic DMARDs can interact with drugs that affect immune surveillance (e.g., live vaccines, other immunosuppressants). TNF inhibitors may reduce the effectiveness of hepatitis B vaccines. Rituximab can enhance the response to certain biologics due to B‑cell depletion.

JAK inhibitors exhibit significant interactions with CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and inducers (e.g., rifampin). Concomitant use with other immunosuppressants can increase infection risk.

Contraindications

• Active severe infection.
• Uncontrolled hepatic or renal disease.
• Pregnancy for certain biologics (e.g., TNF inhibitors) due to potential fetal exposure.
• Known hypersensitivity to the drug or excipients.
• Severe cardiac disease for JAK inhibitors (e.g., history of thromboembolism).

Special Considerations

Use in Pregnancy/Lactation

Methotrexate is contraindicated in pregnancy due to teratogenicity. Sulfasalazine and hydroxychloroquine are generally considered safe in pregnancy, though monitoring is advised. Biologic agents vary: TNF inhibitors are often used during pregnancy when disease activity warrants; however, early third‑trimester exposure may be associated with neonatal immunosuppression. JAK inhibitors are contraindicated due to potential teratogenic effects. Lactation is generally contraindicated for methotrexate and biologics, but hydroxychloroquine is considered compatible with breastfeeding.

Pediatric/Geriatric Considerations

Children may require dose adjustments based on body surface area. Monitoring for growth suppression and developmental delays is necessary. In older adults, comorbidities such as hepatic or renal impairment necessitate careful dose titration and vigilant monitoring for adverse events.

Renal/Hepatic Impairment

Renal dysfunction reduces clearance of methotrexate, leflunomide, and JAK inhibitors, necessitating dose reductions or increased monitoring. Hepatic impairment increases the risk of hepatotoxicity for methotrexate, sulfasalazine, and leflunomide; therapeutic drug monitoring is recommended. Biologic DMARDs are less affected by hepatic or renal function, though underlying liver disease may alter immune responses.

Summary/Key Points

• DMARDs encompass a diverse array of agents, each targeting distinct immunologic pathways.
• Conventional synthetic DMARDs remain foundational in RA management, especially methotrexate.
• Biologic and targeted synthetic DMARDs have expanded therapeutic options, offering disease control for refractory cases.
• Adverse effect profiles necessitate regular laboratory monitoring and patient education regarding signs of toxicity.
• Drug interactions, contraindications, and special populations (pregnancy, adolescents, geriatrics, organ dysfunction) must be carefully evaluated to optimize safety and efficacy.
• Early initiation and sustained therapy are associated with improved long‑term outcomes, underscoring the importance of timely, individualized treatment plans.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.